Search

Your search keyword '"De Boer, Jan Paul"' showing total 347 results
Start Over Author "De Boer, Jan Paul"
347 results on '"De Boer, Jan Paul"'

1. Determinants and mediating mechanisms of quality of life and disease-specific symptoms among thyroid cancer patients: the design of the WaTCh study

Author

Mols, Floortje, Schoormans, Dounya, Netea-Maier, Romana, Husson, Olga, Beijer, Sandra, Van Deun, Katrijn, Zandee, Wouter, Kars, Marleen, Wouters van Poppel, Pleun C. M., Simsek, Suat, van Battum, Patrick, Kisters, Jérôme M. H., de Boer, Jan Paul, Massolt, Elske, van Leeuwaarde, Rachel, Oranje, Wilma, Roerink, Sean, Vermeulen, Mechteld, and van de Poll-Franse, Lonneke

Published
2023
Full Text
View/download PDF

3. Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study

Author

Ansell, Stephen M., Bröckelmann, Paul J., von Keudell, Gottfried, Lee, Hun Ju, Santoro, Armando, Zinzani, Pier Luigi, Collins, Graham P., Cohen, Jonathon B., de Boer, Jan Paul, Kuruvilla, John, Savage, Kerry J., Trněný, Marek, Provencio, Mariano, Jäger, Ulrich, Willenbacher, Wolfgang, Wen, Rachael, Akyol, Alev, Mikita-Geoffroy, Joanna, Shipp, Margaret A., Engert, Andreas, and Armand, Philippe

Published
2023
Full Text
View/download PDF

9. Neoadjuvant immunotherapy with nivolumab and ipilimumab induces major pathological responses in patients with head and neck squamous cell carcinoma

Author

Vos, Joris L., Elbers, Joris B. W., Krijgsman, Oscar, Traets, Joleen J. H., Qiao, Xiaohang, van der Leun, Anne M., Lubeck, Yoni, Seignette, Iris M., Smit, Laura A., Willems, Stefan M., van den Brekel, Michiel W. M., Dirven, Richard, Baris Karakullukcu, M., Karssemakers, Luc, Klop, W. Martin C., Lohuis, Peter J. F. M., Schreuder, Willem H., Smeele, Ludi E., van der Velden, Lilly-Ann, Bing Tan, I., Onderwater, Suzanne, Jasperse, Bas, Vogel, Wouter V., Al-Mamgani, Abrahim, Keijser, Astrid, van der Noort, Vincent, Broeks, Annegien, Hooijberg, Erik, Peeper, Daniel S., Schumacher, Ton N., Blank, Christian U., de Boer, Jan Paul, Haanen, John B. A. G., and Zuur, Charlotte L.

Published
2021
Full Text
View/download PDF

12. Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol

Author

Schaeffers, Anouk W. M. A., primary, Devriese, Lot A., additional, van Gils, Carla H., additional, Dankbaar, Jan Willem, additional, Voortman, Jens, additional, de Boer, Jan Paul, additional, Slingerland, Marije, additional, Hendriks, Mathijs P., additional, Smid, Ernst J., additional, Frederix, Geert W. J., additional, and de Bree, Remco, additional

Published
2023
Full Text
View/download PDF

13. Androgen receptor signalling in macrophages promotes TREM-1-mediated prostate cancer cell line migration and invasion

Author

Cioni, Bianca, Zaalberg, Anniek, van Beijnum, Judy R., Melis, Monique H. M., van Burgsteden, Johan, Muraro, Mauro J., Hooijberg, Erik, Peters, Dennis, Hofland, Ingrid, Lubeck, Yoni, de Jong, Jeroen, Sanders, Joyce, Vivié, Judith, van der Poel, Henk G., de Boer, Jan Paul, Griffioen, Arjan W., Zwart, Wilbert, and Bergman, Andries M.

Published
2020
Full Text
View/download PDF

14. Supplementary Table from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

15. Supplementary Figure from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

16. Supplementary Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

17. Data from Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., primary, Gini, Andrea, primary, Rigter, Lisanne S., primary, Spaander, Manon C.W., primary, Moons, Leon M.G., primary, Bisseling, Tanya M., primary, de Boer, Jan Paul, primary, Verbeek, Wieke H.M., primary, Lugtenburg, Pieternella J., primary, Janus, Cecile P.M., primary, Petersen, Eefke J., primary, Roesink, Judith M., primary, van der Maazen, Richard W.M., primary, Aleman, Berthe M.P., primary, Meijer, Gerrit A., primary, van Leeuwen, Flora E., primary, Snaebjornsson, Petur, primary, Carvalho, Beatriz, primary, van Leerdam, Monique E., primary, and Lansdorp-Vogelaar, Iris, primary

Published
2023
Full Text
View/download PDF

20. Determinants and mediating mechanisms of quality of life and disease-specific symptoms among thyroid cancer patients:the design of the WaTCh study

Author

Mols, Floortje, Schoormans, Dounya, Netea-Maier, Romana, Husson, Olga, Beijer, Sandra, Van Deun, Katrijn, Zandee, Wouter, Kars, Marleen, Wouters van Poppel, Pleun C.M., Simsek, Suat, van Battum, Patrick, Kisters, Jérôme M.H., de Boer, Jan Paul, Massolt, Elske, van Leeuwaarde, Rachel, Oranje, Wilma, Roerink, Sean, Vermeulen, Mechteld, van de Poll-Franse, Lonneke, Mols, Floortje, Schoormans, Dounya, Netea-Maier, Romana, Husson, Olga, Beijer, Sandra, Van Deun, Katrijn, Zandee, Wouter, Kars, Marleen, Wouters van Poppel, Pleun C.M., Simsek, Suat, van Battum, Patrick, Kisters, Jérôme M.H., de Boer, Jan Paul, Massolt, Elske, van Leeuwaarde, Rachel, Oranje, Wilma, Roerink, Sean, Vermeulen, Mechteld, and van de Poll-Franse, Lonneke

Abstract

Background: Thyroid cancer (TC) patients are understudied but appear to be at risk for poor physical and psychosocial outcomes. Knowledge of the course and determinants of these deteriorated outcomes is lacking. Furthermore, little is known about mediating biological mechanisms. Objectives: The WaTCh-study aims to; 1.Examine the course of physical and psychosocial outcomes.2.Examine the association of demographic, environmental, clinical, physiological, and personality characteristics to those outcomes. In other words, who is at risk?3.Reveal the association of mediating biological mechanisms (inflammation, kynurenine pathway) with poor physical and psychological outcomes. In other words, why is a person at risk? Design and methods: Newly diagnosed TC patients from 13 Dutch hospitals will be invited. Data collection will take place before treatment, and at 6, 12 and 24 months after diagnosis. Sociodemographic and clinical information is available from the Netherlands Cancer Registry. Patients fill-out validated questionnaires at each time-point to assess quality of life, TC-specific symptoms, physical activity, anxiety, depression, health care use, and employment. Patients are asked to donate blood three times to assess inflammation and kynurenine pathway. Optionally, at each occasion, patients can use a weighing scale with bioelectrical impedance analysis (BIA) system to assess body composition; can register food intake using an online food diary; and can wear an activity tracker to assess physical activity and sleep duration/quality. Representative Dutch normative data on the studied physical and psychosocial outcomes is already available. Impact: WaTCh will reveal the course of physical and psychosocial outcomes among TC patients over time and answers the question who is at risk for poor outcomes, and why. This knowledge can be used to provide personalized information, to improve scr

Published
2023

21. Low dose cisplatin weekly versus high dose cisplatin every three weeks in primary chemoradiotherapy in head and neck cancer patients with low skeletal muscle mass: The CISLOW-study protocol

Author

MS Hoofd-Hals Chirurgische Oncologie, Cancer, MS Medische Oncologie, Epi Kanker Team A, JC onderzoeksprogramma Kanker, MS Radiologie, Brain, Circulatory Health, MS Radiotherapie, HEE, Child Health, JC onderzoeksprogramma Methodologie, Schaeffers, Anouk W M A, Devriese, Lot A, van Gils, Carla H, Dankbaar, Jan Willem, Voortman, Jens, de Boer, Jan Paul, Slingerland, Marije, Hendriks, Mathijs P, Smid, Ernst J, Frederix, Geert W J, de Bree, Remco, MS Hoofd-Hals Chirurgische Oncologie, Cancer, MS Medische Oncologie, Epi Kanker Team A, JC onderzoeksprogramma Kanker, MS Radiologie, Brain, Circulatory Health, MS Radiotherapie, HEE, Child Health, JC onderzoeksprogramma Methodologie, Schaeffers, Anouk W M A, Devriese, Lot A, van Gils, Carla H, Dankbaar, Jan Willem, Voortman, Jens, de Boer, Jan Paul, Slingerland, Marije, Hendriks, Mathijs P, Smid, Ernst J, Frederix, Geert W J, and de Bree, Remco

Published
2023

22. Determinants and mediating mechanisms of quality of life and disease-specific symptoms among thyroid cancer patients: the design of the WaTCh study

Author

MS Endocriene Oncologie, Cancer, Mols, Floortje, Schoormans, Dounya, Netea-Maier, Romana, Husson, Olga, Beijer, Sandra, Van Deun, Katrijn, Zandee, Wouter, Kars, Marleen, Wouters van Poppel, Pleun C M, Simsek, Suat, van Battum, Patrick, Kisters, Jérôme M H, de Boer, Jan Paul, Massolt, Elske, van Leeuwaarde, Rachel, Oranje, Wilma, Roerink, Sean, Vermeulen, Mechteld, van de Poll-Franse, Lonneke, MS Endocriene Oncologie, Cancer, Mols, Floortje, Schoormans, Dounya, Netea-Maier, Romana, Husson, Olga, Beijer, Sandra, Van Deun, Katrijn, Zandee, Wouter, Kars, Marleen, Wouters van Poppel, Pleun C M, Simsek, Suat, van Battum, Patrick, Kisters, Jérôme M H, de Boer, Jan Paul, Massolt, Elske, van Leeuwaarde, Rachel, Oranje, Wilma, Roerink, Sean, Vermeulen, Mechteld, and van de Poll-Franse, Lonneke

Published
2023

25. Can Epstein-Barr virus DNA load in nasopharyngeal brushings or whole blood predict recurrent nasopharyngeal carcinoma in a non-endemic region? A prospective nationwide study of the Dutch Head and Neck Oncology Cooperative Group

Author

Stoker, Sharon D., Wildeman, Maarten A., Novalic, Zlata, Fles, Renske, van der Noort, Vincent, de Bree, Remco, Braunius, Weibel W., van den Broek, Guido B., Kreike, Bas, Kross, Kenneth W., Juwana, Hedy, Ramayanti, Octavia, Verkuijlen, Sandra A. W. M., de Boer, Jan Paul, Greijer, Astrid E., Middeldorp, Jaap M., and Tan, I. Bing

Published
2016
Full Text
View/download PDF

27. Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy

Author

Ykema, Berbel L.M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H.M., Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Aleman, Berthe M.P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., Lansdorp-Vogelaar, Iris, Ykema, Berbel L.M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H.M., Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Aleman, Berthe M.P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., and Lansdorp-Vogelaar, Iris

Abstract

Background: Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy (IRT) and/or procarbazine have an increased risk of developing colorectal cancer. We investigated the cost-effectiveness of colorectal cancer surveillance in Dutch Hodgkin lymphoma survivors to determine the optimal surveillance strategy for different Hodgkin lymphoma subgroups. Methods: The Microsimulation Screening Analysis-Colon model was adjusted to reflect colorectal cancer and other-cause mortality risk in Hodgkin lymphoma survivors. Ninety colorectal cancer surveillance strategies were evaluated varying in starting and stopping age, interval, and modality [colonoscopy, fecal immunochemical test (FIT, OC-Sensor; cutoffs: 10/20/47 mg Hb/g feces), and multi-target stool DNA test (Cologuard)]. Analyses were also stratified per primary treatment (IRT and procarbazine or procarbazine without IRT). Colorectal cancer deaths averted (compared with no surveillance) and incremental cost-effectiveness ratios (ICER) were primary outcomes. The optimal surveillance strategy was identified assuming a willingness-to-pay threshold of €20,000 per life-years gained (LYG). Results: Overall, the optimal surveillance strategy was annual FIT (47 mg) from age 45 to 70 years, which might avert 70% of colorectal cancer deaths in Hodgkin lymphoma survivors (compared with no surveillance; ICER:€18,000/LYG). The optimal surveillance strategy in Hodgkin lymphoma survivors treated with procarbazine without IRT was biennial FIT (47 mg) from age 45 to 70 years (colorectal cancer mortality averted 56%; ICER:€15,000/LYG), and when treated with IRT and procarbazine, annual FIT (47 mg) surveillance from age 40 to 70 was most cost-effective (colorectal cancer mortality averted 75%; ICER:€13,000/LYG). Conclusions: Colorectal cancer surveillance in Hodgkin lymphoma survivors is cost-effective and should commence earlier than screening occurs in population screening programs. For all subgroups, FIT surveillance was

Published
2022

28. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin’s lymphoma survivors

Author

Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, van Leerdam, Monique E., Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, and van Leerdam, Monique E.

Abstract

Background: Hodgkin’s lymphoma (HL) survivors treated with abdominal radiotherapy and/or procarbazine have an increased risk of developing colorectal neoplasia. Aims: We evaluated the clinicopathological characteristics and risk factors for developing (advanced) neoplasia (AN) in HL survivors. Methods: In all, 101 HL survivors (median age 51 years, median age of HL diagnosis 25 years) underwent colonoscopy and 350 neoplasia and 44 AN (classified as advanced adenomas/serrated lesions or colorectal cancer), mostly right-sided, were detected, as published previously. An average-risk asymptomatic cohort who underwent screening colonoscopy were controls (median age 60 years). Clinicopathological characteristics of AN were evaluated in both groups. Mismatch repair (MMR) status was assessed using immunohistochemistry (MLH1/MSH2/MSH6/PMS2). Logistic regression analysis was performed to evaluate the risk factors for AN in HL survivors, including age at HL diagnosis and interval between HL and colonoscopy. Results: In 101 colonoscopies in HL survivors, AN was primarily classified based on polyp size ≥10 mm, whereas (high-grade)dysplasia was more often seen in AN in controls. An interval between HL diagnosis and colonoscopy >26 years was associated with more AN compared with an interval of <26 years, with an odds ratio for AN of 3.8 (95% confidence interval 1.4–9.1) (p < 0.01). All 39 AN that were assessed were MMR proficient. Conclusions: Colorectal neoplasia in HL survivors differ from average-risk controls; classification AN was primarily based on polyp size (≥10 mm) in HL survivors. Longer follow-up between HL diagnosis and colonoscopy was associated with a higher prevalence of AN in HL survivors.

Published
2022

29. Cost-effectiveness of colorectal cancer surveillance in Hodgkin lymphoma survivors treated with procarbazine and/or infradiaphragmatic radiotherapy

Author

MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Groep Van Diest, Ykema, Berbel Lm, Gini, Andrea, Rigter, Lisanne S, Spaander, Manon Cw, Moons, Leon Mg, Bisseling, Tanya M, de Boer, Jan Paul, Verbeek, Wieke Hm, Lugtenburg, Pieternella J, Janus, Cecile Pm, Petersen, Eefke J, Roesink, Judith M, van der Maazen, Richard W M, Aleman, Berthe Mp, Meijer, Gerrit A, Van Leeuwen, Flora E, Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E, Lansdorp-Vogelaar, Iris, MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Groep Van Diest, Ykema, Berbel Lm, Gini, Andrea, Rigter, Lisanne S, Spaander, Manon Cw, Moons, Leon Mg, Bisseling, Tanya M, de Boer, Jan Paul, Verbeek, Wieke Hm, Lugtenburg, Pieternella J, Janus, Cecile Pm, Petersen, Eefke J, Roesink, Judith M, van der Maazen, Richard W M, Aleman, Berthe Mp, Meijer, Gerrit A, Van Leeuwen, Flora E, Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E, and Lansdorp-Vogelaar, Iris

Published
2022

30. The co-occurrence of both breast- and differentiated thyroid cancer: incidence, association and clinical implications for daily practice

Author

Heelkunde Opleiding, MS CGO, Cancer, Medisch Oncologische Disciplines, MS Endocriene Oncologie, Piek, Marceline W., de Boer, Jan Paul, van Duijnhoven, Frederieke, van der Wal, Jacqueline E., Vriens, Menno, van Leeuwaarde, Rachel S., van der Ploeg, Iris M.C., Heelkunde Opleiding, MS CGO, Cancer, Medisch Oncologische Disciplines, MS Endocriene Oncologie, Piek, Marceline W., de Boer, Jan Paul, van Duijnhoven, Frederieke, van der Wal, Jacqueline E., Vriens, Menno, van Leeuwaarde, Rachel S., and van der Ploeg, Iris M.C.

Published
2022

31. Retrospective analysis of PSMA PET/CT thyroid incidental uptake in adults: incidence, diagnosis, and treatment/outcome in a tertiary cancer referral center and University Medical Center

Author

MS CGO, Cancer, MS Radiologie, MS Endocriene Oncologie, Heelkunde Opleiding, Piek, Marceline W., de Vries, Lisa H., Donswijk, Maarten L., de Keizer, Bart, de Boer, Jan Paul, Lodewijk, Lutske, van Leeuwaarde, Rachel S., Vriens, Menno R., Hartemink, Koen J., van der Ploeg, Iris M.C., MS CGO, Cancer, MS Radiologie, MS Endocriene Oncologie, Heelkunde Opleiding, Piek, Marceline W., de Vries, Lisa H., Donswijk, Maarten L., de Keizer, Bart, de Boer, Jan Paul, Lodewijk, Lutske, van Leeuwaarde, Rachel S., Vriens, Menno R., Hartemink, Koen J., and van der Ploeg, Iris M.C.

Published
2022

32. Disease outcome and associated factors after definitive platinum based chemoradiotherapy for advanced stage HPV-negative head and neck cancer

Author

Pathologie patiënten zorg, Pathologie Opleiding, Cancer, MS Radiotherapie, MS Medische Oncologie, de Roest, Reinout H., van der Heijden, Martijn, Wesseling, Frederik W.R., de Ruiter, Emma J., Heymans, Martijn W., Terhaard, Chris, Vergeer, Marije R., Buter, Jan, Devriese, Lot A., de Boer, Jan Paul, Navran, Arash, Hoeben, Ann, Vens, Conchita, van den Brekel, Michiel, Brakenhoff, Ruud H., Leemans, C. René, Hoebers, Frank, Pathologie patiënten zorg, Pathologie Opleiding, Cancer, MS Radiotherapie, MS Medische Oncologie, de Roest, Reinout H., van der Heijden, Martijn, Wesseling, Frederik W.R., de Ruiter, Emma J., Heymans, Martijn W., Terhaard, Chris, Vergeer, Marije R., Buter, Jan, Devriese, Lot A., de Boer, Jan Paul, Navran, Arash, Hoeben, Ann, Vens, Conchita, van den Brekel, Michiel, Brakenhoff, Ruud H., Leemans, C. René, and Hoebers, Frank

Published
2022

33. Development and external validation of a prediction model for tube feeding dependency for at least four weeks during chemoradiotherapy for head and neck cancer

Author

Afdeling Dietetiek, Cancer, MS Hoofd-Hals Chirurgische Oncologie, MS Medische Oncologie, MS Radiotherapie, Willemsen, Anna C.H., Kok, Annemieke, Baijens, Laura W.J., de Boer, Jan Paul, de Bree, Remco, Devriese, Lot A., Driessen, Chantal M.L., van Herpen, Carla M.L., Hoebers, Frank J.P., Kaanders, Johannes H.A.M., Karsten, Rebecca T., van Kuijk, Sander M.J., Lalisang, Roy I., Navran, Arash, Pereboom, Susanne R., Schols, Annemie M.W.J., Terhaard, Chris H.J., Hoeben, Ann, Afdeling Dietetiek, Cancer, MS Hoofd-Hals Chirurgische Oncologie, MS Medische Oncologie, MS Radiotherapie, Willemsen, Anna C.H., Kok, Annemieke, Baijens, Laura W.J., de Boer, Jan Paul, de Bree, Remco, Devriese, Lot A., Driessen, Chantal M.L., van Herpen, Carla M.L., Hoebers, Frank J.P., Kaanders, Johannes H.A.M., Karsten, Rebecca T., van Kuijk, Sander M.J., Lalisang, Roy I., Navran, Arash, Pereboom, Susanne R., Schols, Annemie M.W.J., Terhaard, Chris H.J., and Hoeben, Ann

Published
2022

34. The association of pretreatment low skeletal muscle mass with chemotherapy dose-limiting toxicity in patients with head and neck cancer undergoing primary chemoradiotherapy with high-dose cisplatin

Author

MS Hoofd-Hals Chirurgische Oncologie, MS Medische Oncologie, Cancer, Bril, Sandra I., Al-Mamgani, Abrahim, Chargi, Najiba, Remeijer, Peter, Devriese, Lot A., de Boer, Jan Paul, de Bree, Remco, MS Hoofd-Hals Chirurgische Oncologie, MS Medische Oncologie, Cancer, Bril, Sandra I., Al-Mamgani, Abrahim, Chargi, Najiba, Remeijer, Peter, Devriese, Lot A., de Boer, Jan Paul, and de Bree, Remco

Published
2022

35. Clinicopathological features and risk factors for developing colorectal neoplasia in Hodgkin’s lymphoma survivors

Author

MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Algemene Pat.zorg, Pathologie Groep Van Diest, Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, van Leerdam, Monique E., MS MDL 1, Cancer, MS Hematologie, Regenerative Medicine and Stem Cells, MS Radiotherapie, Pathologie Algemene Pat.zorg, Pathologie Groep Van Diest, Ykema, Berbel L.M., Rigter, Lisanne S., Spaander, Manon C.W., Moons, Leon M.G., Bisseling, Tanya M., Aleman, Berthe M.P., Dekker, Evelien, Verbeek, Wieke H.M., Kuipers, Ernst J., de Boer, Jan Paul, Lugtenburg, Pieternella J., Janus, Cecile P.M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W.M., Meijer, Gerrit A., Schaapveld, Michael, van Leeuwen, Flora E., Carvalho, Beatriz, Snaebjornsson, Petur, and van Leerdam, Monique E.

Published
2022

38. Development and external validation of a prediction model for tube feeding dependency for at least four weeks during chemoradiotherapy for head and neck cancer

Author

Willemsen, Anna C.H., primary, Kok, Annemieke, additional, Baijens, Laura W.J., additional, de Boer, Jan Paul, additional, de Bree, Remco, additional, Devriese, Lot A., additional, Driessen, Chantal M.L., additional, van Herpen, Carla M.L., additional, Hoebers, Frank J.P., additional, Kaanders, Johannes H.A.M., additional, Karsten, Rebecca T., additional, van Kuijk, Sander M.J., additional, Lalisang, Roy I., additional, Navran, Arash, additional, Pereboom, Susanne R., additional, Schols, Annemie M.W.J., additional, Terhaard, Chris H.J., additional, and Hoeben, Ann, additional

Published
2022
Full Text
View/download PDF

41. Cost-Effectiveness of Colorectal Cancer Surveillance in Hodgkin Lymphoma Survivors Treated with Procarbazine and/or Infradiaphragmatic Radiotherapy.

Author

Ykema, Berbel L. M., Gini, Andrea, Rigter, Lisanne S., Spaander, Manon C. W., Moons, Leon M. G., Bisseling, Tanya M., de Boer, Jan Paul, Verbeek, Wieke H. M., Lugtenburg, Pieternella J., Janus, Cecile P. M., Petersen, Eefke J., Roesink, Judith M., van der Maazen, Richard W. M., Aleman, Berthe M. P., Meijer, Gerrit A., van Leeuwen, Flora E., Snaebjornsson, Petur, Carvalho, Beatriz, van Leerdam, Monique E., and Lansdorp-Vogelaar, Iris

Abstract

Background: Hodgkin lymphoma survivors treated with infradiaphragmatic radiotherapy (IRT) and/or procarbazine have an increased risk of developing colorectal cancer. We investigated the cost-effectiveness of colorectal cancer surveillance in Dutch Hodgkin lymphoma survivors to determine the optimal surveillance strategy for different Hodgkin lymphoma subgroups. Methods: The Microsimulation Screening Analysis-Colon model was adjusted to reflect colorectal cancer and other-cause mortality risk in Hodgkin lymphoma survivors. Ninety colorectal cancer surveillance strategies were evaluated varying in starting and stopping age, interval, and modality [colonoscopy, fecal immunochemical test (FIT, OC-Sensor; cutoffs: 10/20/47 µg Hb/g feces), and multi-target stool DNA test (Cologuard)]. Analyses were also stratified per primary treatment (IRT and procarbazine or procarbazine without IRT). Colorectal cancer deaths averted (compared with no surveillance) and incremental cost-effectiveness ratios (ICER) were primary outcomes. The optimal surveillance strategy was identified assuming a willingness-to-pay threshold of €20,000 per life-years gained (LYG). Results: Overall, the optimal surveillance strategy was annual FIT (47 µg) from age 45 to 70 years, which might avert 70% of colorectal cancer deaths in Hodgkin lymphoma survivors (compared with no surveillance; ICER:€18,000/LYG). The optimal surveillance strategy in Hodgkin lymphoma survivors treated with procarbazine without IRT was biennial FIT (47 µg) from age 45 to 70 years (colorectal cancer mortality averted 56%; ICER:€15,000/LYG), and when treated with IRT and procarbazine, annual FIT (47 µg) surveillance from age 40 to 70 was most cost-effective (colorectal cancer mortality averted 75%; ICER:€13,000/LYG). Conclusions: Colorectal cancer surveillance in Hodgkin lymphoma survivors is cost-effective and should commence earlier than screening occurs in population screening programs. For all subgroups, FIT surveillance was the most cost-effective strategy. Impact: Colorectal cancer surveillance should be implemented in Hodgkin lymphoma survivors. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

42. Second Cancer Risk Up to 40 Years after Treatment for Hodgkinʼs Lymphoma

Author

Schaapveld, Michael, Aleman, Berthe M.P., van Eggermond, Anna M., Janus, Cécile P.M., Krol, Augustinus D.G., van der Maazen, Richard W.M., Roesink, Judith, Raemaekers, John M.M., de Boer, Jan Paul, Zijlstra, Josée M., van Imhoff, Gustaaf W., Petersen, Eefke J., Poortmans, Philip M.P., Beijert, Max, Lybeert, Marnix L., Mulder, Ina, Visser, Otto, Louwman, Marieke W.J., Krul, Inge M., Lugtenburg, Pieternella J., and van Leeuwen, Flora E.

Published
2015
Full Text
View/download PDF

45. Retrospective Analysis of PSMA PET/CT Thyroid Incidental Uptake in Adults: Incidence, Diagnosis and Treatment/outcome in a Tertiary Cancer Referral Center and an Academic Hospital

Author

Piek, Marceline W, primary, de Vries, Lisa H., additional, Donswijk, Maarten, additional, de Keizer, Bart, additional, de Boer, Jan Paul, additional, Lodewijk, Lutske, additional, Leeuwaarde, Rachel S. van, additional, Vriens, Menno R., additional, Hartemink, Koen J., additional, and Ploeg, Iris M.C. van der, additional

Published
2021
Full Text
View/download PDF

46. HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Author

Ansell, Stephen, primary, Bröckelmann, Paul, additional, von Keudell, Gottfried, additional, Lee, Hun Ju, additional, Santoro, Armando, additional, Zinzani, Pier Luigi, additional, Collins, Graham, additional, Cohen, Jonathon, additional, De Boer, Jan Paul, additional, Kuruvilla, John, additional, Savage, Kerry, additional, Trněný, Marek, additional, Provencio, Mariano, additional, Jaeger, Ulrich, additional, Willenbacher, Wolfgang, additional, Swanink, Rene, additional, Shipp, Margaret, additional, Engert, Andreas, additional, and Armand, Philippe, additional

Published
2021
Full Text
View/download PDF

47. Poster: HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)

Author

Ansell, Stephen, primary, Bröckelmann, Paul, additional, von Keudell, Gottfried, additional, Lee, Hun Ju, additional, Santoro, Armando, additional, Zinzani, Pier Luigi, additional, Collins, Graham, additional, Cohen, Jonathon, additional, De Boer, Jan Paul, additional, Kuruvilla, John, additional, Savage, Kerry, additional, Trněný, Marek, additional, Provencio, Mariano, additional, Jaeger, Ulrich, additional, Willenbacher, Wolfgang, additional, Swanink, Rene, additional, Shipp, Margaret, additional, Engert, Andreas, additional, and Armand, Philippe, additional

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results